Synmosa Biopharma Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Synmosa Biopharma heeft een totaal eigen vermogen van NT$8.2B en een totale schuld van NT$2.4B, wat de schuld-eigenvermogensverhouding op 29.6% brengt. De totale activa en totale passiva bedragen respectievelijk NT$12.1B en NT$3.9B. De EBIT Synmosa Biopharma is NT$668.2M waardoor de rentedekking 16.5 is. Het heeft contanten en kortetermijnbeleggingen van NT$1.8B.

Belangrijke informatie

29.6%

Verhouding schuld/eigen vermogen

NT$2.43b

Schuld

Rente dekkingsratio	16.5x
Contant	NT$1.83b
Aandelen	NT$8.22b
Totaal verplichtingen	NT$3.85b
Totaal activa	NT$12.07b

Recente financiële gezondheidsupdates

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Jan 05

Recent updates

Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

Apr 04

If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Mar 08

Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 31

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Jan 05

Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 09

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( NT$4.8B ) 4114 } overtreffen de korte termijn passiva ( NT$2.2B ).

Langlopende schulden: De kortetermijnactiva 4114 ( NT$4.8B ) overtreffen de langetermijnschulden ( NT$1.7B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 7.3% ) 4114 wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van 4114 is de afgelopen 5 jaar gedaald van 73.7% naar 29.6%.

Schuldendekking: De schuld van 4114 wordt goed gedekt door de operationele kasstroom ( 21.9% ).

Rentedekking: De rentebetalingen op de schuld van 4114 worden goed gedekt door EBIT ( 16.5 x dekking).

Synmosa Biopharma Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Recent updates

Second quarter 2024 earnings released: EPS: NT$0.53 (vs NT$0.42 in 2Q 2023)

Synmosa Biopharma Corporation to Report Q2, 2024 Results on Aug 13, 2024

Dividend of NT$0.60 announced

Synmosa Biopharma Corporation Announces Cash Dividend, Payable on September 13, 2024

First quarter 2024 earnings released: EPS: NT$0.48 (vs NT$0.35 in 1Q 2023)

Synmosa Biopharma Corporation to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: EPS: NT$1.61 (vs NT$2.25 in FY 2022)

Synmosa Biopharma Corporation, Annual General Meeting, May 30, 2024

Synmosa Biopharma Corporation Announces Changes in Fifth Session of the Remuneration Committee

Third quarter 2023 earnings released: EPS: NT$0.35 (vs NT$0.32 in 3Q 2022)

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: NT$0.46 (vs NT$1.13 in 2Q 2022)

Upcoming dividend of NT$0.56 per share at 1.4% yield

Synmosa Biopharma Corporation Announces Cash Dividend, Payable on September 15, 2023

Synmosa Biopharma Corporation Appoints Tu, San-Chien as Additional Independent Director

New minor risk - Shareholder dilution

Synmosa Biopharma Corporation announced that it expects to receive TWD 950 million in funding

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2023

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2023

Investor sentiment improved over the past week

Synmosa Biopharma Corporation Provides Earnings Guidance for the Year 2022

Third quarter 2022 earnings released: EPS: NT$0.35 (vs NT$0.21 in 3Q 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$0.35 (vs NT$0.21 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: NT$1.24 (vs NT$0.23 in 2Q 2021)

Upcoming dividend of NT$0.51 per share

Investor sentiment improved over the past week

Synmosa Biopharma Corporation Announces Changes to the Compensation Committee

First quarter 2022 earnings released: EPS: NT$0.42 (vs NT$0.20 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: NT$1.02 (vs NT$2.20 in FY 2020)

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2022

Third quarter 2021 earnings released: EPS NT$0.24 (vs NT$0.25 in 3Q 2020)

Upcoming dividend of NT$0.30 per share

Second quarter 2021 earnings released: EPS NT$0.29 (vs NT$1.66 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$0.23 (vs NT$0.26 in 1Q 2020)

Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

Synmosa Biopharma Corporation Approves Cash Dividends

Synmosa Biopharma Corporation, Annual General Meeting, May 25, 2021

Full year 2020 earnings released: EPS NT$2.46 (vs NT$0.20 in FY 2019)

Revenue beats expectations

If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

New 90-day low: NT$24.05

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Third quarter 2020 earnings released: EPS NT$0.28

New 90-day high - NT$27.60

Price target raised to NT$28.00

New 90-day high - NT$26.95

First half earnings released

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven